Travere Q2: FILSPARI Sales Surge 96% to $141M, FSGS Launch Gains Traction
TVTX has more than doubled off its 52-week low of $15.42.
Summary
Travere Therapeutics posted Q2 2026 results highlighted by FILSPARI net sales of $141.1 million, a 96% year-over-year leap, propelled by the FSGS launch and ongoing IgAN expansion. The quarter closed with $489.2 million in cash, and the pipeline update included pegtibatinase Phase 3 data anticipated in the second half of 2027.
Key Events · Earnings and Guidance · TVTX
-
FILSPARI Sales Surge 96%
Q2 2026 FILSPARI net product sales reached $141.1 million, nearly double the $71.9 million in Q2 2025, driven by the new FSGS indication and continued IgAN growth. Total revenue was $169.6 million.
-
Strong Patient Demand
2,012 new patient start forms (PSFs) were received in Q2 2026, reflecting robust uptake of FILSPARI in both FSGS and IgAN.
-
Cash Position and Convertible Note Activity
Cash, equivalents, and marketable securities totaled $489.2 million at June 30, 2026. The company issued $525 million of 0.5% convertible notes due 2032 and repurchased $221 million of 2029 notes, incurring a $40 million inducement expense.
-
Pipeline Progress
Pegtibatinase Phase 3 HARMONY Study topline data expected in 2H 2027. Civorebrutinib in-licensing closed in July 2026 with a $112.5 million upfront payment. FILSPARI patent allowance extends coverage into 2037.
Analysis · TVTX · Life Sciences
FILSPARI is rapidly becoming a cornerstone commercial asset for Travere, with second-quarter sales nearly doubling year-over-year to $141 million—fueled by the new FSGS indication and sustained IgAN growth. Demand signals are unmistakable: 2,012 new patient start forms arrived in the quarter. The balance sheet remains well fortified at $489 million in cash, following a $525 million convertible note offering and the repurchase of $221 million of 2029 notes, though a $40 million inducement expense pushed the GAAP loss wider. Looking ahead, the pipeline is gathering momentum: pegtibatinase Phase 3 data is on track for late 2027, and the civorebrutinib deal closed in July with a $112.5 million upfront payment, broadening the rare kidney disease portfolio. Trading near its 52-week high, the stock reflects market confidence in the FILSPARI launch trajectory.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 29.6% of the 1615 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TVTX was trading at $62.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2B. The 52-week trading range was $15.42 to $60.10. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.